Suppr超能文献

伐昔洛韦一种新的儿科制剂的体内和体外适口性测试。

In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir.

作者信息

Bastiaans Diane E T, Immohr Laura I, Zeinstra Gertrude G, Strik-Albers Riet, Pein-Hackelbusch Miriam, van der Flier Michiel, de Haan Anton F J, Boelens Jaap Jan, Lankester Arjan C, Burger David M, Warris Adilia

机构信息

Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.

Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, Düsseldorf, Germany.

出版信息

Br J Clin Pharmacol. 2017 Dec;83(12):2789-2797. doi: 10.1111/bcp.13396. Epub 2017 Sep 20.

Abstract

AIMS

The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the new paediatric formulation (test formulation) compared to the reference formulation was investigated.

METHODS

In vivo palatability testing was performed in a randomized, two-period, multicentre, cross-over study. Children and their parents scored the liking of the new paediatric valaciclovir formulation and the reference formulation on a 100 mm visual analogue scale (VAS). To support formulation development and palatability testing, electronic tongue measurements were applied.

RESULTS

The electronic tongue measurement indicated taste-masking capabilities for three different formulations in the developmental phase. A glycerol-based formulation was further tested and compared to the reference formulation prepared out of crushed and suspended tablets. The mean difference (95% CI) in VAS scores between both formulations, as indicated by the children (n = 20), was 2.4 (-8.5, 13) mm, in favour of the new paediatric valaciclovir formulation. The mean (95% CI) difference in VAS scores indicated by the parents (n = 20) was -0.9 (-12, 9.8) mm.

CONCLUSION

The palatability of the new paediatric valaciclovir formulation was considered non-inferior to the reference formulation prepared out of crushed tablets. We were able to optimize the study design and number of children to be included in the palatability testing by using electronic tongue measurements.

摘要

目的

评估伐昔洛韦新儿科制剂在儿童及其父母中的适口性:研究新儿科制剂(试验制剂)与参比制剂相比的非劣效性。

方法

在一项随机、两阶段、多中心、交叉研究中进行体内适口性测试。儿童及其父母使用100毫米视觉模拟量表(VAS)对新儿科伐昔洛韦制剂和参比制剂的喜好程度进行评分。为支持制剂开发和适口性测试,应用了电子舌测量。

结果

电子舌测量表明处于研发阶段的三种不同制剂具有掩味能力。对一种基于甘油的制剂进行了进一步测试,并与由碾碎和混悬片剂制备的参比制剂进行比较。儿童(n = 20)给出的两种制剂VAS评分的平均差值(95%CI)为2.4(-8.5,13)毫米,新儿科伐昔洛韦制剂更受青睐。父母(n = 20)给出的VAS评分平均(95%CI)差值为-0.9(-12,9.8)毫米。

结论

新儿科伐昔洛韦制剂的适口性被认为不劣于由碾碎片剂制备的参比制剂。通过使用电子舌测量,我们能够优化研究设计和适口性测试中纳入的儿童数量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80ba/5698570/327ee0e378f5/BCP-83-2789-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验